NCT06135844 is a EARLY_PHASE1 clinical trial of Purell Hand Sanitizer in Virus, sponsored by Leciel Bono.

Who is sponsoring NCT06135844?

NCT06135844 is sponsored by Leciel Bono.

What drugs are being tested in NCT06135844?

Interventions in NCT06135844: Purell Hand Sanitizer, Medical Grade Mineral Oil.

What condition does NCT06135844 study?

NCT06135844 studies Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis.

Is NCT06135844 still recruiting?

NCT06135844 is currently status unknown. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT06135844

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hand Sanitizer Use for Herpes Simplex Virus-1

Status unknown EARLY_PHASE1 Last updated 18 November 2023

What this trial tests

EARLY_PHASE1 trial testing Purell Hand Sanitizer in Virus in 20 participants. Status unknown.

Timeline

8 April 2022

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	Leciel Bono
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	8 April 2022
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	3 locations across United States

Drugs / interventions tested

Purell Hand Sanitizer — full drug profile →
Medical Grade Mineral Oil — full drug profile →

Conditions studied

Virus — all drugs for Virus →
HSV-1 — all drugs for HSV-1 →
Herpes Simplex 1 — all drugs for Herpes Simplex 1 →
Herpes Simplex Labialis — all drugs for Herpes Simplex Labialis →

Sponsor

Leciel Bono — full company profile →

Who can join

Adults 18 to 99, any sex, with Virus or HSV-1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Virus

Currently open trials in the same condition.

NCT03911388 — HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06135844 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Leciel Bono
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06135844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing